VIA combination treatment

PreclinicalSmall molecule

VIA combination treatment is one of 3 small molecule programs targeting Epithelioid Sarcoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Epithelioid SarcomaActive, not recruiting

Epithelioid SarcomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Epithelioid Sarcoma

#DrugCompanyPhaseTrials

Tazverik

EEpizyme, Inc.

Preclinical

3 2

Doxorubicin HCL

MMemorial Sloan Kettering Cancer Center

Phase 1

1 3

VIA combination treatment

PPeking University People's Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Epithelioid Sarcoma1 trial

Irinotecan and Anlotinib for Epithelioid Sarcoma

Withdrawn·PPeking University People's Hospital·N/A·NCT05656222

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VIA combination treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VIA combination treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VIA combination treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPeking University People's Hospital

VIA combination treatment

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Epithelioid Sarcoma1 trial

References

Drug Info

Quick Facts

Related News